San Diego???s Trius Therapeutics, which registered for a $78 million IPO in November, postponed its plans in March to conform its Phase 3 protocol for its antibiotic drug candidate, torezolid phosphate, to accomodate new guidance issued by the FDA.So what are the factors affecting IPOs, and what kind of guidance are San Diego???s experienced CEOs and other experts offering about taking startups pu